How to Lose Weight During Perimenopause

How to lose weight during perimenopause is a question many women in their forties and fifties find themselves asking, often after noticing that approaches that once worked no longer seem effective. Perimenopause brings hormonal shifts, disrupted sleep, and changes in fat distribution that make weight management genuinely more complex. This article explains why perimenopausal weight gain happens, how hormonal changes affect metabolism, and what dietary, lifestyle, and medical options are supported by current UK clinical guidance, including when to speak to your GP.

Why is it so hard to lose weight during perimenopause?

Losing weight during perimenopause is harder because falling oestrogen, poor sleep, and a shift of fat towards the abdomen all disrupt energy balance in ways that go beyond diet and activity alone.

Losing weight during perimenopause is harder than at other life stages because falling oestrogen levels, disrupted sleep, and shifting fat distribution all influence energy balance in ways that go beyond simple dietary intake and activity output. Perimenopause, the transitional phase leading up to the final menstrual period, typically begins in a woman's mid-to-late forties, though it can start earlier, and may last anywhere from a few years to over a decade (NHS, Menopause overview).^[1][2]

During this time, the body tends to redistribute fat away from the hips and thighs and towards the abdomen. This visceral fat is metabolically active and is associated with a higher risk of cardiovascular disease and type 2 diabetes, which is why perimenopausal weight gain is a clinical concern rather than simply a cosmetic one (NICE NG23: Menopause: diagnosis and management).

Sleep disruption is extremely common during perimenopause, largely due to night sweats and anxiety. Poor sleep is associated with changes in appetite-regulating hormones, including raised ghrelin and reduced leptin, which may increase appetite and cravings for calorie-dense foods. Fatigue also reduces motivation to exercise, creating a cycle that can be difficult to break without targeted support.

Understanding these biological drivers is the first step. Weight gain during perimenopause is not simply a matter of willpower, and approaches that worked in earlier decades may need to be adapted to account for these hormonal and metabolic shifts.

How do hormonal changes affect your weight and metabolism?

Declining oestrogen reduces insulin sensitivity and resting metabolic rate, while falling testosterone reduces muscle mass, collectively promoting abdominal fat gain and making calorie management harder.

Declining oestrogen is the central hormonal driver of perimenopausal weight gain. Oestrogen is associated with the regulation of fat storage, insulin sensitivity, and resting metabolic rate. As ovarian oestrogen production becomes erratic and eventually falls, the body may compensate partly by increasing fat storage in adipose tissue, which can itself produce small amounts of oestrogen through a process called aromatisation. This shift is associated with the accumulation of abdominal fat (British Menopause Society consensus statements on metabolic health at menopause).

Progesterone levels also fluctuate and decline during perimenopause. Lower progesterone relative to oestrogen may contribute to fluid retention and bloating, which some women mistake for fat gain. Testosterone, which is present in women in smaller quantities, also declines gradually and is associated with a reduction in lean muscle mass. Because muscle tissue uses more energy at rest than fat tissue, a reduction in muscle mass may lower the basal metabolic rate, meaning the body requires fewer calories to maintain its current weight.

Insulin sensitivity may decrease during perimenopause, partly as a consequence of reduced oestrogen and partly due to increased visceral fat.^[4] This can make it harder for cells to use glucose efficiently, which may promote further fat storage and increase the risk of developing type 2 diabetes. Women with a personal or family history of insulin resistance or polycystic ovary syndrome (PCOS) may be particularly affected.

Cortisol, the stress hormone, may be elevated in some women during perimenopause, particularly those experiencing significant psychological symptoms such as anxiety or low mood. Raised cortisol is associated with abdominal fat deposition and may further affect insulin sensitivity. These hormonal interactions are complex and vary between individuals; the statements above reflect associations reported in the clinical literature rather than universal rules.

What diet and lifestyle changes actually help during perimenopause?

A protein-rich, whole-food diet combined with resistance training at least twice weekly and 150 minutes of moderate aerobic activity is the most evidence-supported approach for perimenopausal weight management.

A diet rich in protein, fibre, and whole foods, combined with regular resistance exercise, is the most evidence-supported approach to managing weight during perimenopause. No single diet has been shown to be uniquely effective for perimenopausal women, but several principles are consistently supported by clinical evidence and align with NHS and UK Chief Medical Officers' guidance.

Dietary strategies worth prioritising include:

• Increasing protein intake: Protein supports muscle preservation, promotes satiety, and has a higher thermic effect than carbohydrates or fat. Aim to include a source of protein (such as eggs, fish, legumes, poultry, or dairy) at each meal (British Dietetic Association).

• Reducing ultra-processed foods and added sugars: These contribute to poor glycaemic control and provide little nutritional value. Replacing them with whole grains, vegetables, and healthy fats supports more stable blood glucose levels (NHS Better Health: Lose weight).

• Eating regularly: Skipping meals may increase cravings and make it harder to maintain consistent energy levels. Some women find time-restricted eating helpful, but this should be discussed with a GP or dietitian, particularly if there is any history of disordered eating.

• Limiting alcohol: Alcohol disrupts sleep, adds empty calories, and may worsen hot flushes.

• Supporting bone health: Weight-bearing exercise and adequate calcium and vitamin D intake are particularly relevant during perimenopause, when bone density may begin to decline.

Lifestyle changes with strong evidence include:

• Resistance training: Lifting weights or using resistance bands on at least two days per week helps preserve and rebuild muscle mass, counteracting the metabolic slowdown associated with hormonal decline. This aligns with UK Chief Medical Officers' physical activity guidelines, which recommend muscle-strengthening activity on at least two days per week alongside at least 150 minutes of moderate aerobic activity.^[6][7]

• Aerobic exercise: Brisk walking, swimming, or cycling supports cardiovascular health and mood.

• Prioritising sleep: Addressing night sweats and sleep disruption, whether through behavioural strategies or medical treatment, has downstream benefits for appetite regulation and energy levels.

• Stress management: Mindfulness, yoga, and adequate rest may help support overall wellbeing during this life stage.

Can medication or HRT help with weight management in perimenopause?

HRT can indirectly support weight management by improving sleep and reducing fatigue, while licensed medicines such as tirzepatide or semaglutide may be prescribed for eligible women following clinical assessment.

Hormone replacement therapy (HRT) does not directly cause weight loss, but it can address some of the hormonal drivers of perimenopausal weight gain, including sleep disruption, muscle loss, and abdominal fat redistribution. NICE guideline NG23 on menopause recommends that HRT be offered to women with perimenopausal symptoms after a discussion of the benefits and risks, and it remains the most effective treatment for vasomotor symptoms such as hot flushes and night sweats.^[3] By improving sleep quality and reducing fatigue, HRT may indirectly support healthier eating and exercise habits.

For women with a BMI of 35 or above and weight-related health conditions, NICE technology appraisals have recommended certain licensed weight management medicines as adjuncts to lifestyle intervention. NHS access to these medicines depends on national commissioning decisions and local Integrated Care Board (ICB) pathways, and is typically provided through specialist weight management services rather than routine GP prescribing. Licensed options that a prescriber may consider include orlistat (available on the NHS), GLP-1 receptor agonists such as semaglutide (Wegovy, with weekly doses up to 2.4 mg, and a higher authorised weekly maintenance dose of 7.2 mg now also available) and liraglutide (Saxenda), and the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro), which is authorised by the MHRA for both type 2 diabetes and chronic weight management in adults.^[9][10] Orforglipron (Foundayo) is also now licensed in the UK for chronic weight management.^[11] This list is not exhaustive, and the options available through any given pathway will depend on individual clinical assessment and local commissioning. These medicines are prescribed only where clinically appropriate following a full assessment. Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate. Bolt Pharmacy is a GPhC-registered online pharmacy (GPhC regulates pharmacy premises in Great Britain; pharmacy regulation in Northern Ireland is the responsibility of the PSNI) offering online weight-management consultations with prescriber review and pharmacist support.

Weight-management medicines, including GLP-1-based treatments, are not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception while taking these medicines and should inform their prescriber promptly if they are planning a pregnancy or become pregnant, as treatment will need to be stopped. The UK SmPC for tirzepatide advises using an additional non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase, because tirzepatide may slow gastric absorption of oral contraceptives.^[12][13] This additional contraception requirement is specific to tirzepatide; women taking other weight-management medicines should check the relevant product information or ask their prescriber or pharmacist.

Any decision about medication should involve a full discussion with a prescriber about individual risk factors, current medications, and reproductive status.

When should you speak to your GP about perimenopausal weight gain?

Speak to your GP if weight gain is rapid, unexplained, or accompanied by fatigue, increased thirst, or low mood, as these may indicate thyroid dysfunction, insulin resistance, or another treatable condition.

You should speak to your GP about perimenopausal weight gain if it is rapid, unexplained, or accompanied by other symptoms such as fatigue, increased thirst, changes in bowel habit, or low mood, as these may indicate an underlying condition requiring investigation. Gradual weight gain during perimenopause is common, but it is not inevitable, and a GP can help distinguish between weight gain driven by hormonal changes and that caused by thyroid dysfunction, insulin resistance, or other treatable conditions.

NICE guidance recommends that GPs assess cardiovascular risk, blood glucose, and lipid levels in perimenopausal women, particularly those with central obesity.^[15] A fasting blood glucose or HbA1c test can help identify prediabetes or type 2 diabetes risk, and thyroid function tests can rule out hypothyroidism, which shares several symptoms with perimenopause including weight gain, fatigue, and low mood.^[16] Blood pressure and waist circumference are also commonly assessed in primary care as part of cardiovascular risk evaluation (NICE: Cardiovascular disease risk assessment and lipid modification; NICE NG28: Type 2 diabetes in adults).

Your GP can also discuss whether HRT is appropriate for you, refer you to a dietitian or structured weight management programme, or consider whether a licensed weight management medicine might be suitable. NHS specialist weight management services are available in many areas, and referral criteria vary by Integrated Care Board (ICB).

Seek advice from your GP if you notice any of the following:

• Unexplained weight gain of more than a few kilograms over a short period

• Significant changes in appetite, thirst, or urination

• Persistent low mood, anxiety, or cognitive difficulties alongside weight changes

• Difficulty losing weight despite sustained dietary and lifestyle changes

For urgent symptoms such as chest pain or severe breathlessness, call 999. For non-emergency medical advice outside GP hours, contact NHS 111. Suspected side effects from any prescribed medicine can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Menopause and perimenopause.
2. Symptoms of menopause and perimenopause.
3. Menopause: identification and management (NG23).
4. Perimenopause and metabolic vulnerability: hormones, body composition and lifestyle changes. Climacteric..
5. Late, but Not Early, Night Sleep Loss Compromises Neuroendocrine Appetite Regulation and the Desire for Food. Nutrients..
6. UK Chief Medical Officers' physical activity guidelines.
7. Physical activity guidelines for adults aged 19 to 64.
8. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
9. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
10. Tirzepatide.
11. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
12. Tirzepatide – BNF.
13. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral contraceptive absorption. PubMed..
14. GLP-1 medicines for weight loss and diabetes: what you need to know.
15. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238).
16. Underactive thyroid (hypothyroidism).

Frequently Asked Questions